Tag - daiichi-sankyo-co

 
 

DAIICHI SANKYO CO

Japan Times
BUSINESS / Companies
Jun 7, 2023
AstraZeneca’s Japan partner to go solo on future cancer drugs
Daiichi Sankyo is expanding its sales and development staff overseas, aiming to boost production capacity so that it can handle its cancer drugs business entirely on its own.
Japan Times
BUSINESS
Jan 13, 2023
Japan's Daiichi Sankyo applies for approval of mRNA COVID vaccine
An approval would give Japan a homegrown mRNA vaccine — a vaccine type that has played a dominant role in the country's COVID-19 inoculation drive to this point.
Japan Times
JAPAN / Science & Health
Nov 15, 2022
Japan's Daiichi Sankyo says mRNA COVID vaccine successful in booster trial
Approval would give Japan a home-grown source for mRNA vaccines, which have made up the bulk of its COVID-19 inoculations to date.
Japan Times
COMMENTARY / World
Jun 8, 2022
The drug that could transform breast cancer treatment
The early success of Enhertu, from AstraZeneca and Daiichi Sankyo, bodes well for an entire class of medicines that may one day replace conventional chemotherapy.
Japan Times
BUSINESS
Dec 27, 2021
Tardy COVID-19 vaccine makers under fire for trials in developing nations
Vaccine developers at the testing phase now are seeking developing countries where vaccination rates remain low and the virus is still active.
Japan Times
BUSINESS / Companies
Sep 6, 2021
Daiichi Sankyo positions its COVID-19 vaccine as a booster in Japan
Daiichi Sankyo is aiming for full regulatory approval by the second half of next year.
Japan Times
JAPAN / Science & Health
Mar 23, 2021
Japanese firms launch domestic clinical trials for COVID-19 vaccines
Even as Daiichi Sankyo and KM Biologics begin work to prove their shots' efficacy and safety, the public is unlikely to have access to them until fiscal 2022 at the earliest.
Japan Times
JAPAN
Mar 12, 2021
Japanese drugmaker starts AstraZeneca vaccine production
Daiichi Sankyo Co. on Thursday began the vial filling and packaging of the vaccine using undiluted solutions provided by AstraZeneca.
JAPAN / Science & Health
Aug 31, 2020
Daiichi Sankyo's COVID-19 vaccine candidate selected by Japanese drug discovery body
Daiichi Sankyo Co. said on Monday that its mRNA-based COVID-19 vaccine candidate was selected for inclusion in a drug discovery program by the Japan Agency for Medical Research and Development.
Japan Times
BUSINESS / Companies
Jul 28, 2020
Astra to pay Daiichi up to $6 billion for new cancer drug
AstraZeneca is forging ahead to become a global oncology powerhouse, even as it works on a vaccine for the coronavirus pandemic.
Japan Times
JAPAN / Science & Health
Jun 12, 2020
Daiichi Sankyo sees clinical test for genetic COVID-19 vaccine in March
The vaccine contains messenger RNA that causes cells to produce proteins that could trigger the body to produce effective antibodies.
Japan Times
JAPAN / Science & Health
Jun 16, 2019
Drug devised to replace chemotherapy may reshape cancer care
A class of drugs is emerging that can attack cancer cells in the body without damaging surrounding healthy ones. They have the potential to replace chemotherapy and its disruptive side effects, reshaping the future of cancer care.
Japan Times
BUSINESS / Companies
Mar 29, 2019
AstraZeneca bets $6.9 billion that Daiichi Sankyo therapy will transform cancer treatment
Britain's AstraZeneca's biggest deal in recent memory give it access to the Japanese drugmaker's promising but difficult to pronounce cancer treatment: trastuzumab deruxtecan.
Japan Times
BUSINESS / Companies
Sep 29, 2017
Opioids demand rises in Japan as seniors use drugs to ease pain and improve quality of life
Selling painkillers in Japan used to be like pulling teeth. That was until baby boomers discovered how analgesics could take the sting from arthritis, diabetic nerve damage and the ravages of cancer.
Japan Times
BUSINESS / Companies
Aug 2, 2017
Daiichi Sankyo settles U.S. lawsuits over intestinal damage from blood-pressure drugs, paying $300 million
Daiichi Sankyo Inc. has settled thousands of lawsuits alleging its blood-pressure drugs caused intestinal damage, bringing to $339 million the amount the drugmaker has paid over the medicines.
BUSINESS / Companies
May 6, 2016
Daiichi Sankyo awarded damages over cover-up at Indian ex-subsidiary
Daiichi Sankyo Co. said Friday that an international arbitration court has ordered former shareholders of an Indian firm it acquired in 2008 to pay the drugmaker around ¥56.2 billion ($524 million) for concealing critical information.
Japan Times
BUSINESS / Companies
Feb 9, 2015
Growth concerns loom for Daiichi Sankyo on drug warning
Daiichi Sankyo Co. risks losing a slice of revenue to generic-medicine competition next year. Now, the drugmaker's plans to fill the gap have hit a roadblock and investors worry that growth may flounder.
Japan Times
BUSINESS / Companies
Sep 29, 2014
Daiichi Sankyo to buy Ambit to strengthen cancer product line
Daiichi Sankyo Co. has agreed to buy U.S.-based Ambit Biosciences Corp. for as much as $410 million to bolster its pipeline of cancer treatments.

Longform

Historically, kabuki was considered the entertainment of the merchant and peasant classes, a far cry from how it is regarded today.
For Japan's oldest kabuki theater, the show must go on